Janssen Sciences Ireland UC

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Janssen Sciences Ireland UC sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Janssen Sciences Ireland UC: 7 sponsored US clinical trials, none currently recruiting.

Janssen Sciences Ireland UC sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1, with 1 trials.

Upper-quartile sponsor footprint

Janssen Sciences Ireland UC sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

NCT00980538
TERMINATED Phase 2

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

NCT04056611
COMPLETED Phase 2

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

NCT03982186
COMPLETED Phase 2

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

NCT03361956
TERMINATED Phase 1

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
COMPLETED Phase 3

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

NCT02431247
COMPLETED Phase 2

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2

Therapeutic Areas

HIV-1 1
HIV Infections 1

How the Janssen Sciences Ireland UC early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: HIV-1 (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Janssen Sciences Ireland UC: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Janssen Sciences Ireland UC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Janssen Sciences Ireland UC3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Janssen Sciences Ireland UC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Janssen Sciences Ireland UC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Janssen Sciences Ireland UC page

7 registered trials is a research-attention snapshot, not an endorsement of Janssen Sciences Ireland UC or any single study.

  • None of Janssen Sciences Ireland UC's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • HIV-1 is the condition Janssen Sciences Ireland UC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Janssen Sciences Ireland UC pipeline card: 7 registered trials from official public datasets.Report a data error.